Veralight has just received CE marking for the Scout DS screening system for type 2 diabetes and impaired glucose tolerance. The system, which has been previously featured on Medgadget, uses fluorescence spectroscopy to detect advanced glycation endproducts (AGEs) in the skin, which are used as biomarkers for diabetes. The advantage of this approach is that it does not require invasive blood tests or fasting and can produce a result in almost 3 minutes allowing for much faster screening of patients.
This has obvious implications for the diabetes explosion which would appear to be upon us.
Some clinical trial data from the press release:
Data from 421 study subjects in the CE filing shows SCOUT DS identified over 60% more people with abnormal glucose tolerance than either the fasting plasma glucose or hemoglobin A1c tests at thresholds established by The World Health Organization. The CE Mark filing was supported by safety and effectiveness studies on a cohort of 738 study subjects. SCOUT DS is Indicated for Use for the noninvasive screening of individuals 18 years or older who are at risk for prediabetes and/or type 2 diabetes to determine whether diagnostic testing is necessary. Prediabetes is defined as impaired glucose tolerance.
Product page: SCOUT DS…